Stock listing

OTC:ARDS Aridis Pharmaceuticals Inc. Stock

Follow Aridis Pharmaceuticals Inc. into a list and get an email when it puts out news.

Share price · OTC:ARDS

$0.0001 USD 0.0000 (0.0%)

Close on Nov 20, 2026

Past year -50.0% · daily closes, Nov 24, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.0001 – $0.0001 USDNov 20, 2026
Volume
1,600 sharesNov 20, 2026
Market cap
$4,457 USDAt the close on Nov 20, 2026 · price × 44.57M shares outstanding
52-week range
$0.0001 – $0.0500 USDLowest and highest trades, Nov 24, 2025 – Nov 20, 2026
Traded on an average day
$2 USDMedian day 565 shares · 25 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026
Aridis Pharmaceuticals Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ARDS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.00010.00000.0%$0.0001$0.0001$0.00011,600
$0.00010.00000.0%$0.0001$0.0001$0.0001900
$0.00010.00000.0%$0.0001$0.0001$0.000112,000
$0.00010.00000.0%$0.0001$0.0001$0.00011,520
$0.00010.00000.0%$0.0001$0.0001$0.0001869,540
$0.00010.00000.0%$0.0001$0.0001$0.00016,100
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.0001-0.0001-50.0%$0.0002$0.0002$0.0001374,480
$0.00020.00000.0%$0.0002$0.0002$0.00021,000
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.00020.00000.0%$0.0002$0.0002$0.000215,100
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.00020.00000.0%$0.0002$0.0002$0.0002195
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.00020.00000.0%$0.0002$0.0002$0.00020
$0.0002+0.0001+100.0%$0.0002$0.0002$0.00021,950
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00013,250
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.000110,000
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001600
$0.00010.00000.0%$0.0001$0.0001$0.0001233
$0.00010.00000.0%$0.0001$0.0001$0.00012,000
$0.00010.00000.0%$0.0001$0.0001$0.000110,561
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.000115,000
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001360
$0.00010.00000.0%$0.0001$0.0001$0.00011,063
$0.00010.00000.0%$0.0001$0.0001$0.00011,067
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.000110,000
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.000110,301
$0.00010.00000.0%$0.0001$0.0001$0.00014,306
$0.00010.00000.0%$0.0001$0.0001$0.00017,079
$0.00010.00000.0%$0.0001$0.0001$0.000111,010
$0.00010.00000.0%$0.0001$0.0001$0.00011,529
$0.00010.00000.0%$0.0001$0.0001$0.0001139
$0.00010.00000.0%$0.0001$0.0001$0.00015,724
$0.00010.00000.0%$0.0001$0.0001$0.00011,029
$0.00010.00000.0%$0.0001$0.0001$0.00011,044
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00012,752
$0.00010.00000.0%$0.0014$0.0014$0.000110
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00011,087
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.0001529
$0.00010.00000.0%$0.0001$0.0001$0.000142,719
$0.00010.00000.0%$0.0001$0.0001$0.0001500
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00012,650
$0.00010.00000.0%$0.0001$0.0001$0.00010
$0.00010.00000.0%$0.0001$0.0001$0.00011,002
Ticker
OTC:ARDS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

Latest news

All Aridis Pharmaceuticals Inc. news

Aridis Pharmaceuticals Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
5 in all · newest Jun 24, 2024 · oldest 2023
Decks
10 decks · latest February 2024

Valuation

price Nov 20, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
-0.21

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Aridis Pharmaceuticals Inc. · OTC:ARDSUS$4,457n/an/an/an/an/an/an/a-0.21
Chimeric Therapeutics Limited · ASX:CHMUS$292,816−US$220,193n/a−0.1×n/a0.2×−262.8%2.5×n/a
CERo Therapeutics Holdings, Inc. · OTC:CEROUS$265,035−US$190,890n/an/an/an/an/an/a1.47
CDT Equity Inc. · NASDAQ:CDTUS$234,109−US$1.49Mn/an/an/a0.0×n/a0.0×1.14
GlucoTrack, Inc. · NASDAQ:GCTKUS$217,049−US$887,951n/an/an/an/an/an/a1.73
Regen BioPharma, Inc. · OTC:RGBPUS$167,528US$167,289n/a0.7×n/an/a−501.4%n/a1.20
CNBX Pharmaceuticals Inc. · OTC:CNBXUS$160,577US$151,090n/an/an/an/an/an/a1.78
Fifty 1 Labs Inc. · OTC:FITYUS$118,532US$282,021n/a6,000×n/an/an/an/a-1.17
GB Sciences, Inc. · OTC:GBLXUS$81,414US$2.07Mn/an/an/an/an/an/a-0.46
Lyra Therapeutics, Inc. · OTC:LYRAUS$53,246US$14.42Mn/a36.2×n/an/an/an/a0.67
ZyVersa Therapeutics, Inc. · OTC:ZVSAUS$810US$1.20Bn/an/an/an/an/an/a-0.56
Median of the othersUS$164,053US$159,19018.5×0.1×−382.1%1.3×1.14

Team and board

Officers

OfficerRole
Vu L. TruongFounder, Chief Executive Officer and Director
Jeffrey J. FesslerActing General Counsel
Elizabeth LeiningerVice President of Regulatory Affairs and Quality
Franco MercklingSenior Vice President, Operations
Bruno FrancoisHead of Limoges Clinical Investigation Center
Hasan JafriChief Medical Officer
Marin KollefDirector of Medical ICU and Respiratory Care Services

Board

DirectorRole
Vu L. TruongFounder, Chief Executive Officer and Director

Events

QuarterResultsShare move
Quarter to Dec 31, 2025Feb 25, 20260.0%
Quarter to Sep 30, 2025Nov 28, 20250.0%
Quarter to Jun 30, 2025Aug 29, 20250.0%
Quarter to Mar 31, 2025May 30, 2025−66.7%
Quarter to Dec 31, 2024Feb 26, 20250.0%
Quarter to Sep 30, 2024Nov 29, 20240.0%
Quarter to Jun 30, 2024Aug 13, 20240.0%
Quarter to Mar 31, 2024May 14, 2024
Quarter to Dec 31, 2023Jan 12, 2024 · After close
Q3 2023Nov 3, 2023 · After close
All 20 quarters
QuarterResultsShare move
Q2 2023Sep 14, 2023 · Before open
Q1 2023May 22, 2023 · After close
Q4 2022Mar 31, 2023 · After close
Q3 2022Nov 21, 2022 · After close
Q2 2022Aug 16, 2022 · Before open
Q1 2022Apr 1, 2022 · Before open
Q4 2021Mar 31, 2022 · After close
Q3 2021Nov 10, 2021 · Before open
Q2 2021Aug 12, 2021 · After close
Q1 2021May 11, 2021 · After close

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (February 2024)Investor deck26 slidesFebruary 2024
Investor Presentation (July 2023)Investor deck27 slidesJuly 2023
Investor Presentation (April 2023)Investor deck26 slidesApril 2023
Investor Presentation (February 2023)Investor deck34 slidesFebruary 2023
Investor Presentation (November 2022)Investor deck30 slidesNovember 2022
Investor Presentation (January 2022)Investor deck30 slidesJan 5, 2022
Investor Day (December 2020)Investor day27 slidesDec 4, 2020
Investor Presentation (June 2020)Investor deck8 slidesJun 26, 2020
Maxim ID Conference 2020Conference9 slidesMay 5, 2020
PEP Talk Conference 2020Conference39 slidesJan 24, 2020

Open Decks

Financials

Annual, in USD

Income statement

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue19.3M1.53M1.00M1.02M2.76M860.0K2.27M2.86M
Cost of revenue23.0M01.93M2.15M
Gross profit1.53M1.00M1.02M2.76M860.0K342.0K714.0K
Research and development25.9M37.9M17.0M24.1M23.0M17.4M6.26M
Selling, general and administrative7.16M7.31M6.45M6.03M3.87M3.16M1.97M3.28M
Operating income-30.0M-43.7M-22.4M-29.1M-24.1M-19.7M-7.88M-7.91M
Depreciation and amortization487.0K435.0K337.0K338.0K283.0K62.0K23.0K27.0K
EBITDA-29.5M-43.3M-22.1M-28.7M-23.8M-19.7M-7.86M-7.88M
Interest expense378.0K245.0K00420.0K0366.0K0
Income before tax-30.4M-43.2M-22.3M-29.7M-22.1M-24.7M-8.42M-8.20M
Income tax378.0K-912.0K-405.0K-695.0K2.43M4.92M538.0K0
Net income-30.7M-42.3M-22.3M-29.0M-22.1M-24.7M-8.42M-8.20M
Earnings per share, basic-1.64-3.44-2.44-3.43-7.02-3.12-1.07

Balance sheet

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash and equivalents4.88M20.0M8.23M20.9M24.2M25.1M22.3M2.89M
Receivables1.24M237.0K368.0K413.0K2.10M67.0K522.0K
Inventory-237.0K-368.0K-413.0K-4.11M
Current assets11.6M26.8M15.1M28.0M24.2M25.3M22.4M3.57M
Property, plant and equipment1.36M1.26M1.01M1.27M750.0K39.0K42.0K
Total assets14.7M26.8M15.1M28.0M31.6M26.5M22.5M3.88M
Accounts payable2.31M5.24M1.89M1.75M2.33M933.0K678.0K402.0K
Current liabilities36.9M33.3M22.4M19.3M5.30M3.17M2.40M5.91M
Long-term debt5.28M276.0K
Total debt6.13M5.98M715.0K
Total liabilities38.9M40.9M23.8M24.3M5.30M15.0M8.76M5.91M
Shareholders' equity-24.2M-13.1M-8.68M3.64M26.3M11.4M13.8M-2.02M
Shares outstanding18.8M12.3M9.17M8.46M3.15M7.89M7.89M

Cash flow

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations-29.1M-22.9M-20.5M-8.16M-24.3M-17.6M-6.09M-4.49M
Capital spending-82.0K-530.0K-367.0K-174.0K-677.0K-698.0K-15.0K-1.00K
Free cash flow-29.2M-23.5M-20.8M-8.33M-24.9M-18.3M-6.11M-4.49M
Cash from investing-82.0K-530.0K-367.0K-174.0K-1.68M-698.0K-15.0K-1.00K
Cash from financing14.8M34.7M8.68M4.99M25.1M21.1M25.5M3.76M
Dividends paid-4.13M-1.36M
Share buybacks7.96M4.99M25.1M21.1M25.8M89.0K
Change in cash-14.4M11.3M-12.2M-3.34M-859.0K2.81M19.4M-738.0K

Open Financials

Cap table

Built by 6ix from Aridis Pharmaceuticals Inc.’s releases

Common shares
44,574,021
Fully diluted
44,574,021

Fully diluted

LineShares
Common shares44,574,021

Share count over time

CountShares
Nov 22, 202644,574,021

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyAs of
Strengthening Families & Communities, LLC3,000<0.01%Sep 30, 2026

Big stakes

StakeStakeSharesDateFiling
Armistice Capital, LLC11.43%5.1MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Isaac Blech
Other companies: X4 Pharmaceuticals, Inc. (Director · Mar 13, 2019 – Mar 13, 2019 · Past); InspireMD Inc. (Director · Jan 22, 2016 – Dec 7, 2016 · Past); Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Dec 31, 2018 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); SpendSmart Networks Inc (Director · Aug 1, 2014 – Jul 19, 2016 · Past); CervoMed Inc. (Director · Jul 24, 2014 – Aug 31, 2016 · Past); Aevi Genomic Medicine LLC (Director · Nov 11, 2013 – Apr 15, 2016 · Past)
Director · Aug 13, 2018 – Aug 13, 2018 · Past
Michael Adrian Nazak
Other companies: AN2 Therapeutics, Inc. (Chief Accounting Officer · Mar 24, 2022 – Feb 15, 2023 · Past)
Chief Financial Officer · Feb 18, 2021 – Feb 18, 2021 · Past
Bruno FrancoisHead of Limoges Clinical Investigation Center · Since at least Nov 4, 2026
Elizabeth LeiningerVice President of Regulatory Affairs and Quality · Since at least Nov 5, 2026
Franco MercklingSenior Vice President, Operations · Since at least Nov 5, 2026
Fred KurlandCFO · Aug 13, 2018 – May 4, 2023 · Past
Hasan JafriChief Medical Officer · Since at least Jun 15, 2020
Jeffrey J. FesslerActing General Counsel · Since at least Nov 5, 2026
Marin KollefDirector of Medical ICU and Respiratory Care Services · Since at least Nov 4, 2026
Robert K CoughlinDirector · Aug 13, 2018 – Aug 13, 2018 · Past
All 11 people
PersonSeat
Vu L. TruongFounder, Chief Executive Officer and Director · Since at least May 12, 2021

Open People

Log in to ask 6ix AI your own questions about Aridis Pharmaceuticals Inc.